We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

285 hedge funds and large institutions have $3.04B invested in Amedisys in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 78 increasing their positions, 101 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $2.85B → $3.04B (+$184M)

1.07% more ownership

Funds ownership: 94.99%96.06% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 1313 (0)

2% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 45

1% less funds holding

Funds holding: 288285 (-3)

23% less repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 101

84% less call options, than puts

Call options by funds: $15.6M | Put options by funds: $97.6M

Holders
285
Holders Change
-3
Holders Change %
-1.04%
% of All Funds
4.09%
Holding in Top 10
13
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.19%
New
44
Increased
78
Reduced
101
Closed
45
Calls
$15.6M
Puts
$97.6M
Net Calls
-$82M
Net Calls Change
-$4.86M
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$33M +$7.2M +73,824 +28%
SGCM
27
Sand Grove Capital Management
United Kingdom
$32.8M -$9.27M -95,010 -22%
HCM
28
Highbridge Capital Management
New York
$31.2M -$29.3K -300 -0.1%
Adage Capital Partners
29
Adage Capital Partners
Massachusetts
$30.5M +$26.7M +273,239 +640%
PAMP
30
Polar Asset Management Partners
Ontario, Canada
$29M +$29.3M +300,000 New
AA
31
AQR Arbitrage
Connecticut
$28.6M -$10.1M -103,696 -26%
Amundi
32
Amundi
France
$28.4M +$1.76M +18,000 +7%
Morgan Stanley
33
Morgan Stanley
New York
$27.8M +$11.5M +117,440 +69%
MAM
34
Melqart Asset Management
United Kingdom
$26.6M -$7.35M -75,348 -21%
LP
35
LMR Partners
United Kingdom
$25.4M -$11.9M -122,012 -32%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$23.5M -$2.57M -26,390 -10%
Northern Trust
37
Northern Trust
Illinois
$22.6M -$706K -7,235 -3%
GCIA
38
Gabelli & Co Investment Advisers
New York
$19.4M -$360K -3,692 -2%
SG Americas Securities
39
SG Americas Securities
New York
$19M +$15.5M +158,398 +413%
Citigroup
40
Citigroup
New York
$18.6M +$1.26M +12,911 +7%
GF
41
Gabelli Funds
New York
$18.5M -$2.38M -24,426 -11%
Squarepoint
42
Squarepoint
New York
$17.6M +$11.4M +117,274 +181%
DKCM
43
Davidson Kempner Capital Management
New York
$15.9M +$7.89M +80,857 +96%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$15.9M +$2.79M +28,590 +21%
Grantham, Mayo, Van Otterloo & Co (GMO)
45
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$13.7M +$13.8M +141,521 New
NAM
46
Nexpoint Asset Management
Texas
$13.5M +$13.7M +140,196 New
GAM
47
Gotham Asset Management
New York
$13.4M +$1.38M +14,139 +11%
N
48
Natixis
France
$12.3M +$6.13M +62,775 +98%
BHMP
49
Bardin Hill Management Partners
New York
$12M +$378K +3,871 +3%
Renaissance Technologies
50
Renaissance Technologies
New York
$11.6M -$790K -8,100 -6%

AMED Hedge Fund Activity: Q3 2024 in Review

285 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q3 2024, worth a combined $3.04B — up 6.5% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of AMED and 44 opened new positions — a net loss of 1 holder — while 101 trimmed existing stakes and 78 added.

The largest buyer was Kite Lake Capital Management (UK), opening a new position worth an estimated $52.6M. The largest seller was Goldman Sachs, cutting an estimated $98.5M.

  • 285 institutional investors held Amedisys (AMED) as of Q3 2024, down from 288 in Q2 2024.
  • Funds reported $3.04B of Amedisys stock for Q3 2024, up 6.5% quarter-over-quarter.
  • 44 funds opened new Amedisys positions in Q3 2024 and 45 closed out, a net change of -1 holder.
  • The largest Amedisys buyer in Q3 2024 was Kite Lake Capital Management (UK), an estimated $52.6M added.
  • The largest Amedisys seller in Q3 2024 was Goldman Sachs, an estimated $98.5M sold.

Based on aggregated 13F filings for Q3 2024.